TC
FOLD

TFS Capital’s Amicus Therapeutics FOLD Stock Holding History

TFS Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-104,274
Closed -$1.14M – 964
2015
Q1 		$1.14M Sell
104,274
-386,917
-79% -$3.41M 0.11% 298
2014
Q4 		$4.09M Buy
491,191
+71,002
+17% +$487K 0.39% 37
2014
Q3 		$2.5M Buy
420,189
+201,095
+92% +$1.05M 0.22% 134
2014
Q2 		$732K Buy
219,094
+88,218
+67% +$207K 0.06% 518
2014
Q1 		$271K Sell
130,876
-455,775
-78% -$1.14M 0.02% 1068
2013
Q4 		$1.38M Sell
586,651
-463,968
-44% -$1.02M 0.07% 442
2013
Q3 		$2.44M Sell
1,050,619
-166,150
-14% -$417K 0.11% 268
2013
Q2 		$2.83M Buy
+1,216,769
New +$3.74M 0.12% 241

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TFS Capital's FOLD Position: Q2 2015 in Review

TFS Capital sold out of Amicus Therapeutics (FOLD) in Q2 2015, closing a stake of 104,274 shares — an estimated $1.14M sold.

TFS Capital first reported a position in FOLD in Q2 2013 and held it in 8 quarters. The position peaked at $4.09M in Q4 2014. 140 funds tracked by Wall St. Rank hold FOLD as of Q2 2015.

  • TFS Capital reported no remaining Amicus Therapeutics position as of Q2 2015 after selling out during the quarter.
  • TFS Capital sold 104,274 Amicus Therapeutics shares in Q2 2015, an estimated $1.14M.
  • TFS Capital first reported a position in Amicus Therapeutics in Q2 2013 and held it in 8 quarters.
  • TFS Capital's Amicus Therapeutics position peaked at $4.09M in Q4 2014.
  • 140 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.